<DOC>
	<DOCNO>NCT01688206</DOCNO>
	<brief_summary>This multi-center , open-label study evaluate safety , pharmacokinetics , pharmacodynamics preliminary efficacy vanucizumab single agent combination atezolizumab participant locally advance metastatic solid tumor . Cohorts participant receive escalate dos vanucizumab , fix dose vanucizumab ( MTD and/or recommend phase two dose [ RP2D ] ) , fix dose vanucizumab combination atezolizumab , intravenously every 2 week .</brief_summary>
	<brief_title>A Study Vanucizumab ( RO5520985 ) Alone Combination With Atezolizumab Participants With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participants histologically confirm epithelial ovarian , fallopian tube primary peritoneal cancer Participants must platinum resistant disease define progression within &lt; 6 month completion minimum 4 platinum therapy cycle OR Participants must platinum refractory disease , define progression platinum base chemotherapy Less equal ( &lt; = ) 2 prior line systemic therapy The participant willing consent undergo pretreatment treatment core excisional biopsy tumor Measurable disease determine RECIST 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Adequate hematological function Adequate liver function Adequate renal function Adequate coagulation Adequate cardiovascular function Recovery reversible adverse event previous anticancer therapy baseline Common Terminology Criteria Adverse Events ( CTCAE ) Grade ( G ) 1 , except alopecia ( grade ) &lt; = G 2 sensory peripheral neuropathy Participants primary central nervous system ( CNS ) tumor CNS tumor involvement . Participants metastatic CNS tumor may participate trial condition define protocol Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 Cycle 1 , abdominal surgery , abdominal intervention significant abdominal traumatic injury within 60 day prior Day 1 Cycle 1 anticipation need major surgical procedure course study nonrecovery side effect procedure Significant cardiovascular/cerebrovascular disease within 6 month prior study drug administration Known human immuno deficiency virus ( HIV ) infection know active hepatitis B hepatitis C virus infection active tuberculosis Participants previously treat vascular endothelial growth factor ( VEGF ) A inhibitor agent target Angiopoietin ( Ang ) 1/2 and/or Tyrosineprotein kinase receptor2 History intraabdominal inflammatory process within last 12 month , limited , diverticulitis , peptic ulcer disease , colitis Any prior radiotherapy pelvis abdomen Treatment systemic immunostimulatory agent , include limited , interferon ( IFN ) alpha , IFNbeta , interleukin ( IL ) 2 , conjugate IL2 cytokine within 6 week five halflives drug , whichever longer , prior screen History bowel obstruction and/or clinical sign symptoms gastrointestinal obstruction , include subocclusive disease relate underlying disease ( however , participant signs/symptoms sub/occlusive syndrome/bowel obstruction time initial diagnosis may enrol receive definitive [ surgical ] treatment symptom resolution ) . History abdominal fistula tracheooesophageal fistula , gastrointestinal perforation intraabdominal abscess , unless occur resolve initial diagnosis unrelated underlying cancer disease . Evidence rectosigmoid involvement pelvic examination bowel involvement Computed tomography ( CT ) Chronic daily treatment nonsteroidal antiinflammatory drug ( NSAID ) ( occasional use symptomatic relief medical condition , example , headache , fever allow ) Treatment systemic immunosuppressive medication include , limited , cyclophosphamide , azathioprine , methotrexate , thalidomide , antitumor necrosis factor agent within 2 week prior study drug administration Previous treatment checkpoint inhibitor ( e.g . anti Programmed death [ PD ] 1 , antiPDligand 1 , anti Cytotoxic Tlymphocyteassociated molecule4 ) prior treatment cluster differentiation ( CD ) 137 agonist antibody drug target T cell costimulation immune checkpoint blockade therapy History autoimmune disease include , limited systemic lupus erythematosus ( SLE ) , Sjögren 's syndrome , glomerulonephritis , multiple sclerosis , rheumatoid arthritis , vasculitis , systemic immune activation , inflammatory bowel disease , vascular thrombosis associate antiphospholipid syndrome , Wegener 's granulomatosis , GuillainBarré syndrome , Bell 's palsy History idiopathic pulmonary fibrosis , organize pneumonia ( e.g . bronchiolitis obliterans ) , druginduced pneumonitis , idiopathic pneumonitis , evidence active pneumonitis screen chest CT scan Prior allogeneic bone marrow transplantation prior solid organ transplantation Administration live , attenuate vaccine within 4 week Cycle1 Day1 anticipation live attenuate vaccine require study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>